AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review

Date: September 13, 2017
Pages: 42
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A7C337C2521EN
Leaflet:

Download PDF Leaflet

AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review
AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody product candidates for the treatment of inflammatory, autoimmune and atopic diseases. The company develops its product candidates through its proprietary antibody discovery technology platform, somatic hypermutation (SHM). Its product candidates include anti-IL-33 antibody (ANB020), for the treatment of moderate-to-severe adult atopic dermatitis, food allergies and asthma; anti-IL-36R antibody (ANB019) intended for the treatment generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of human autoimmune diseases. The company has partnership with TESARO and Celgene, to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

AnaptysBio Inc Key Recent Developments

Aug 24,2017: AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors
Aug 10,2017: AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates
May 11,2017: AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
Mar 08,2017: AnaptysBio Announces 2016 Operating Results and Pipeline Progress
Jan 11,2017: AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

AnaptysBio Inc - Key Facts
AnaptysBio Inc - Key Employees
AnaptysBio Inc - Key Employee Biographies
AnaptysBio Inc - Major Products and Services
AnaptysBio Inc - History
AnaptysBio Inc - Company Statement
AnaptysBio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

AnaptysBio Inc - Business Description
AnaptysBio Inc - Corporate Strategy
AnaptysBio Inc - SWOT Analysis
SWOT Analysis - Overview
AnaptysBio Inc - Strengths
AnaptysBio Inc - Weaknesses
AnaptysBio Inc - Opportunities
AnaptysBio Inc - Threats
AnaptysBio Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
AnaptysBio Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 24, 2017: AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors
Aug 10, 2017: AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates
May 11, 2017: AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
Mar 08, 2017: AnaptysBio Announces 2016 Operating Results and Pipeline Progress
Jan 11, 2017: AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer
Sep 26, 2016: AnaptysBio Announces Checkpoint Receptor Agonist Antibody Portfolio
Apr 18, 2016: AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

AnaptysBio Inc, Key Facts
AnaptysBio Inc, Key Employees
AnaptysBio Inc, Key Employee Biographies
AnaptysBio Inc, Major Products and Services
AnaptysBio Inc, History
AnaptysBio Inc, Subsidiaries
AnaptysBio Inc, Key Competitors
AnaptysBio Inc, Ratios based on current share price
AnaptysBio Inc, Annual Ratios
AnaptysBio Inc, Annual Ratios (Cont.1)
AnaptysBio Inc, Annual Ratios (Cont.2)
AnaptysBio Inc, Interim Ratios
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
AnaptysBio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

AnaptysBio Inc, Performance Chart (2013 - 2016)
AnaptysBio Inc, Ratio Charts
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Regeneron Pharmaceuticals Inc
Novartis AG
Genentech Inc
DBV Technologies SA
AstraZeneca Plc
Skip to top


Ask Your Question

AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: